Emerging Research and News in Prostate Cancer Imaging — February 2025

For patients at high-risk for biochemical recurrence of prostate cancer, PSMA PET/CT findings revealed that 77 percent had one or more prostate lesions after undergoing local radiation therapy or radical prostatectomy, according to a recent study.

In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.

New research findings suggest that image quality and lesion conspicuity are significantly lower with ultrafast breast MRI in comparison to standard dynamic contrast-enhanced breast MRI.

An interview with two experts to discuss newly released guidance for using standardized MRI protocols for patients with this condition.

For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.

Irrespective of age or O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, gross total resection of IDH wild-type glioblastomas was associated with a median overall survival of 32.6 months, according to new MRI research.